Detalhe da pesquisa
1.
Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.
Immunity
; 55(3): 512-526.e9, 2022 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263569
2.
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 627(8004): 646-655, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418879
3.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 627(8005): E11, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38480897
4.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38816613
5.
CD96 functions as a co-stimulatory receptor to enhance CD8+ T cell activation and effector responses.
Eur J Immunol
; 50(6): 891-902, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043568
6.
CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1.
Proc Natl Acad Sci U S A
; 115(50): E11731-E11740, 2018 12 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30504141
7.
Combined PD-L1/TGFß blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors.
Nat Commun
; 14(1): 4703, 2023 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543621
8.
Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Cancer Res
; 79(7): 1493-1506, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30679180
9.
Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models.
Cancer Immunol Res
; 7(6): 963-976, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31064777